Liver fibrosis in metabolic dysfunction-associated steatotic liver disease: epidemiology, risk stratification and therapeutics

Fuliang Li, Hongmei Li, Dulguun Juramt, Kai Kou, Frank Tacke, Lanlan Chen

Open source

DOI
10.1136/bmjgast-2026-002343
Published
2026-07
Container
BMJ Open Gastroenterology
Publisher
BMJ
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1136/bmjgast-2026-002343,
  title = {Liver fibrosis in metabolic dysfunction-associated steatotic liver disease: epidemiology, risk stratification and therapeutics},
  author = {Fuliang Li and Hongmei Li and Dulguun Juramt and Kai Kou and Frank Tacke and Lanlan Chen},
  year = {2026},
  journal = {BMJ Open Gastroenterology},
  doi = {10.1136/bmjgast-2026-002343},
  url = {https://doi.org/10.1136/bmjgast-2026-002343}
}

RIS

TY  - JOUR
TI  - Liver fibrosis in metabolic dysfunction-associated steatotic liver disease: epidemiology, risk stratification and therapeutics
AU  - Fuliang Li
AU  - Hongmei Li
AU  - Dulguun Juramt
AU  - Kai Kou
AU  - Frank Tacke
AU  - Lanlan Chen
PY  - 2026
JO  - BMJ Open Gastroenterology
DO  - 10.1136/bmjgast-2026-002343
UR  - https://doi.org/10.1136/bmjgast-2026-002343
ER  - 

APA

Li, F., Li, H., Juramt, D., Kou, K., Tacke, F., & Chen, L. (2026). Liver fibrosis in metabolic dysfunction-associated steatotic liver disease: epidemiology, risk stratification and therapeutics. BMJ Open Gastroenterology. https://doi.org/10.1136/bmjgast-2026-002343

Source records